585 related articles for article (PubMed ID: 28940301)
1. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
Chaoul A; Milbury K; Spelman A; Basen-Engquist K; Hall MH; Wei Q; Shih YT; Arun B; Valero V; Perkins GH; Babiera GV; Wangyal T; Engle R; Harrison CA; Li Y; Cohen L
Cancer; 2018 Jan; 124(1):36-45. PubMed ID: 28940301
[TBL] [Abstract][Full Text] [Related]
2. Sleep moderates the effects of Tibetan yoga for women with breast cancer undergoing chemotherapy.
Sinclair KL; Kiser E; Ratcliff CG; Chaoul A; Hall MH; Rinpoche TW; Cohen L
Support Care Cancer; 2022 May; 30(5):4477-4484. PubMed ID: 35107599
[TBL] [Abstract][Full Text] [Related]
3. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
Liu L; Rissling M; Natarajan L; Fiorentino L; Mills PJ; Dimsdale JE; Sadler GR; Parker BA; Ancoli-Israel S
Sleep; 2012 Feb; 35(2):237-45. PubMed ID: 22294814
[TBL] [Abstract][Full Text] [Related]
4. Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer.
Mortimer JE; Waliany S; Dieli-Conwright CM; Patel SK; Hurria A; Chao J; Tiep B; Behrendt CE
Cancer; 2017 May; 123(10):1810-1816. PubMed ID: 28061004
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
7. Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer.
Wielgus KK; Berger AM; Hertzog M
Oncol Nurs Forum; 2009 Jan; 36(1):38-48. PubMed ID: 19136337
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series.
Galantino ML; Greene L; Daniels L; Dooley B; Muscatello L; O'Donnell L
Explore (NY); 2012; 8(2):127-35. PubMed ID: 22385567
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer.
Yates P; Aranda S; Hargraves M; Mirolo B; Clavarino A; McLachlan S; Skerman H
J Clin Oncol; 2005 Sep; 23(25):6027-36. PubMed ID: 16135471
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
12. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue.
Berger AM; Kuhn BR; Farr LA; Von Essen SG; Chamberlain J; Lynch JC; Agrawal S
J Clin Oncol; 2009 Dec; 27(35):6033-40. PubMed ID: 19884558
[TBL] [Abstract][Full Text] [Related]
13. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy.
Liu L; Fiorentino L; Natarajan L; Parker BA; Mills PJ; Sadler GR; Dimsdale JE; Rissling M; He F; Ancoli-Israel S
Psychooncology; 2009 Feb; 18(2):187-94. PubMed ID: 18677716
[TBL] [Abstract][Full Text] [Related]
18. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
